Patents by Inventor Hideyoshi Harashima

Hideyoshi Harashima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210052629
    Abstract: The present invention relates to a mitochondria-targeted lipid membrane structure encapsulating a nucleic acid represented by any of the following a) to d): a) an RNA comprising, in this order, a nucleotide sequence of a first mitochondrial tRNA, a nucleotide sequence of an mRNA encoding a target protein, and a nucleotide sequence of a second mitochondrial tRNA, wherein the nucleotide sequence of the mRNA has one or more UGAs as a tryptophan codon; b) a DNA comprising a nucleotide sequence of a promoter and a nucleotide sequence complementary to the RNA of a); c) an RNA comprising a nucleotide sequence of an mRNA encoding a target protein, and a nucleotide sequence of a poly(A) chain present at the 3? end side thereof, wherein the nucleotide sequence of the mRNA has one or more UGAs as a tryptophan codon, AUG as a start codon, and UAA as a stop codon; and d) a DNA comprising a nucleotide sequence of a promoter and a nucleotide sequence complementary to the RNA of c).
    Type: Application
    Filed: February 25, 2019
    Publication date: February 25, 2021
    Applicant: LUCA Science Inc.
    Inventors: Hideyoshi HARASHIMA, Yuma YAMADA, Kana SOMIYA, Hitoshi OSAKA
  • Publication number: 20200129431
    Abstract: A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I): (R1)(R2)C(OH)—(CH3)a—(O—CO)b—X??(I) [in the formula, a represents an integer of 3 to 5; b represents an integer of 0 or 1; R1 and R2 each independently represents a linear hydrocarbon group that may have —CO—O—; and X represents a 5- to 7-membered non-aromatic heterocyclic group or a group represented by Formula (B) (in the formula, d represents an integer of 0 to 3, and R3 and R4 each independently represents a C1-4 alkyl group or a C2-4 alkenyl group, where, R3 and R4 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (where, one or two C1-4 alkyl groups or C2-4 alkenyl groups may be substituted on the ring)].
    Type: Application
    Filed: June 15, 2018
    Publication date: April 30, 2020
    Inventors: Hideyoshi Harashima, Yusuke Sato
  • Publication number: 20200032214
    Abstract: An object of the present invention is to provide a novel myocardial stem cell for transplantation which enables maintenance of a therapeutic effect on and/or preventive effect against cardiac failure for a prolonged period, a method for producing the myocardial stem cell, and a cell preparation containing the myocardial stem cell. [Solution] The present invention relates to a method for producing a myocardial stem cell to be used for treatment and/or prevention of cardiac failure, the method comprising the step of introducing a complex of a mitochondria-targeting carrier and a mitochondria activating agent into a myocardial stem cell; a cell produced by the method and a cell preparation containing the cell; and a liposome to be used for producing the cell. According to the present invention, there can be provided a myocardial stem cell which is capable of maintaining a therapeutic effect and/or preventive effect by cell transplantation for a prolonged period.
    Type: Application
    Filed: November 16, 2017
    Publication date: January 30, 2020
    Applicant: LUCA Science Inc.
    Inventors: Hideyoshi HARASHIMA, Yuma YAMADA, Jiro ABE, Atsuhito TAKEDA
  • Patent number: 10485874
    Abstract: Hyaluronic acid modified with sphingosine-1-phosphate, and a medicine comprising the hyaluronic acid as an active ingredient, wherein the medicine can alleviate hepatic disorder caused by hypoxia/reoxygenation by protecting the liver sinusoidal endothelial cells, and the medicine can prevent and/or treat liver failure due to liver transplantation, hepatectomy, or other surgeries associated with liver ischemia/reperfusion.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: November 26, 2019
    Assignees: Kewpie Corporation, University of Tsukuba
    Inventors: Hideyoshi Harashima, Mamoru Hyodo, Naoyuki Toriyabe, Nobuhiro Ohkohchi, Takafumi Tamura, Naoki Sano
  • Patent number: 10385030
    Abstract: The present invention aims to provide a cationic lipid that can be used as a nucleic acid delivery carrier, a lipid membrane structure using a cationic lipid, a nucleic acid-introducing agent using a cationic lipid, and a method of achieving nucleic acid introduction by using a nucleic acid-introducing agent containing a cationic lipid. A lipid membrane structure containing a cationic lipid represented by the formula (1) wherein each symbol is as defined in the DESCRIPTION, is superior in the stability in blood and tumor accumulation property. A nucleic acid-introducing agent using the cationic lipid can achieve high nucleic acid delivery efficiency of nucleic acid to be delivered into the cytoplasm.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: August 20, 2019
    Assignees: NOF CORPORATION, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Yuta Nakai, Kota Tange, Hidetaka Akita, Hideyoshi Harashima, Ryohei Togashi, Naoya Miura, Mio Maeta
  • Publication number: 20190110986
    Abstract: The present invention provides an O/W type emulsion having a volume median diameter of not more than 100 nm and containing a compound represented by the formula (1) wherein Xa and Xb are each independently X1, X2 or a 1,4-piperazinediyl group; s is 1 or 2, R4 is an alkyl group having 1-6 carbon atoms, na and nb are each independently 0 or 1, R1a, R1b, R2a and R2b are each independently an alkylene group having 1-6 carbon atoms, Ya and Yb are each independently an ester bond, or the like, and R3a and R3b are each independently a liposoluble vitamin residue or the like.
    Type: Application
    Filed: June 29, 2016
    Publication date: April 18, 2019
    Applicants: NOF CORPORATION, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Kota TANGE, Yuta NAKAI, Hidetaka AKITA, Hiroki TANAKA, Ayaka WATANABE, Naoya MIURA, Hideyoshi HARASHIMA
  • Patent number: 10182987
    Abstract: A lipid membrane structure encapsulating an siRNA inside thereof and containing a lipid compound of the formula (I) as a lipid component (R1 and R2 represent CH3—(CH2)n—CH?CH—CH2—CH?CH—(CH2)m—, n represents an integer of 3 to 5, m represents an integer of 6 to 10, p represents an integer of 2 to 7, and R3 and R4 represent a C1-4 alkyl group or a C2-4 alkenyl group.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: January 22, 2019
    Assignee: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Hideyoshi Harashima, Yusuke Sato, Shota Warashina, Hiroto Hatakeyama, Mamoru Hyodo, Takashi Nakamura
  • Publication number: 20180362999
    Abstract: [Problem] To provide a novel expression vector capable of effectively expressing a target protein in mitochondria and suppressing undesirable expression of the target protein in cell organelles other than mitochondria. [Solution] The present invention provides a recombinant expression vector for expressing a target protein in mitochondria of animal cells, and a lipid membrane structure having the vector encapsulated therein, wherein the recombinant expression vector has a promoter sequence exhibiting a transcription activity in the nuclei of animal cells, and has, under the control of the promoter sequence, a coding region which codes a target protein and includes one or more TGAs as codons corresponding to tryptophan. The recombinant expression vector according to the present invention can more efficiently and selectively express a target protein in mitochondria, and can be used as a more safe and effective drug for treating mitochondrial diseases.
    Type: Application
    Filed: November 28, 2016
    Publication date: December 20, 2018
    Applicant: National University Corporation Hokkaido University
    Inventors: Hideyoshi HARASHIMA, Yuma YAMADA, Takuya ISHIKAWA, Hidetaka AKITA
  • Patent number: 10092655
    Abstract: The invention provides a cationic lipid capable of achieving higher intracellular delivery efficiency than conventional cationic lipids, when used as a lipid membrane structure which is a carrier for delivering functional nucleic acid. The cationic lipid is represented by the formula (1): wherein each symbol is as defined herein.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: October 9, 2018
    Assignees: NOF CORPORATION, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Shota Sasaki, Masaki Ota, Kazuhiro Kubo, Hideyoshi Harashima, Hidetaka Akita, Hiroto Hatakeyama, Yuki Noguchi, Kota Tange, Yuta Nakai, Nayuta Shimizu
  • Publication number: 20180155304
    Abstract: The present invention aims to provide a cationic lipid that can be used as a nucleic acid delivery carrier, a lipid membrane structure using a cationic lipid, a nucleic acid-introducing agent using a cationic lipid, and a method of achieving nucleic acid introduction by using a nucleic acid-introducing agent containing a cationic lipid. A lipid membrane structure containing a cationic lipid represented by the formula (1) wherein each symbol is as defined in the DESCRIPTION, is superior in the stability in blood and tumor accumulation property. A nucleic acid-introducing agent using the cationic lipid can achieve high nucleic acid delivery efficiency of nucleic acid to be delivered into the cytoplasm.
    Type: Application
    Filed: January 29, 2016
    Publication date: June 7, 2018
    Applicants: NOF CORPORATION, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Yuta NAKAI, Kota TANGE, Hidetaka AKITA, Hideyoshi HARASHIMA, Ryohei TOGASHI, Naoya MIURA, Mio MAETA
  • Publication number: 20170274086
    Abstract: The invention provides a cationic lipid capable of achieving higher intracellular delivery efficiency than conventional cationic lipids, when used as a lipid membrane structure which is a carrier for delivering functional nucleic acid. The cationic lipid is represented by the formula (1): wherein each symbol is as defined herein.
    Type: Application
    Filed: August 7, 2015
    Publication date: September 28, 2017
    Applicants: NOF CORPORATION, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Shota SASAKI, Masaki OTA, Kazuhiro KUBO, Hideyoshi HARASHIMA, Hidetaka AKITA, Hiroto HATAKEYAMA, Yuki NOGUCHI, Kota TANGE, Yuta NAKAI, Nayuta SHIMIZU
  • Publication number: 20170273905
    Abstract: A lipid membrane structure encapsulating an siRNA inside thereof and containing a lipid compound of the formula (I) as a lipid component (R1 and R2 represent CH3—(CH2)n—CH?CH—CH2—CH?CH—(CH2)m—, n represents an integer of 3 to 5, m represents an integer of 6 to 10, p represents an integer of 2 to 7, and R3 and R4 represent a C1-4 alkyl group or a C2-4 alkenyl group.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 28, 2017
    Applicant: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Hideyoshi Harashima, Yusuke Sato, Shota Warashina, Hiroto Hatakeyama, Mamoru Hyodo, Takashi Nakamura
  • Patent number: 9717687
    Abstract: [Problem] To provide: a lipid membrane structure which has such a particle diameter that the lipid membrane structure can be sterilized by filtration, contains a lipid that is bound to a peptide composed of multiple arginine residues as a constituent lipid, and includes a bacterial cell component having dispersibility in a non-polar solvent; and a method for producing a lipid membrane structure which has such a particle diameter that the lipid membrane structure can be sterilized by filtration and includes a substance of interest having dispersibility in a non-polar solvent. [Solution] A lipid membrane structure which has such a particle diameter that the lipid membrane structure can be sterilized by filtration, contains a lipid that is bound to a peptide composed of multiple arginine residues as a constituent lipid, and includes a bacterial cell component having dispersibility in a non-polar solvent.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: August 1, 2017
    Assignees: National University Corporation Hokkaido University, Japan BCG Laboratory, University of Tsukuba
    Inventors: Hideyoshi Harashima, Takashi Nakamura, Masafumi Fukiage, Megumi Higuchi, Hideyuki Akaza, Jun Miyazaki, Akihiro Nakaya
  • Patent number: 9708628
    Abstract: The present invention relates to a compound represented by the formula (1) wherein Xa and Xb are each independently X1 or X2; s is 1 or 2, R4 is an alkyl group having 1-6 carbon atoms, na and nb are each independently 0 or 1, R1a and R1b are each independently an alkylene group having 1-6 carbon atoms, R2a and R2b are each independently an alkylene group having 1-6 carbon atoms, Ya and Yb are each independently an ester bond, an amide bond, a carbamate bond, an ether bond or a urea bond, and R3a and R3b are each independently a sterol residue, a liposoluble vitamin residue or an aliphatic hydrocarbon group having 12-22 carbon atoms, and use thereof.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: July 18, 2017
    Assignees: NOF Corporation, National University Corporation Hokkaido University
    Inventors: Kota Tange, Masaya Arai, Kazuhiro Kubo, Hidetaka Akita, Hideyoshi Harashima, Hiroto Hatakeyama, Ryohei Ishiba, Masami Ukawa, Hiroki Tanaka
  • Publication number: 20170056509
    Abstract: Hyaluronic acid modified with sphingosine-1-phosphate, and a medicine comprising the hyaluronic acid as an active ingredient, wherein the medicine can alleviate hepatic disorder caused by hypoxia/reoxygenation by protecting the liver sinusoidal endothelial cells, and the medicine can prevent and/or treat liver failure due to liver transplantation, hepatectomy, or other surgeries associated with liver ischemia/reperfusion.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 2, 2017
    Inventors: Hideyoshi HARASHIMA, Mamoru HYODO, Naoyuki TORIYABE, Nobuhiro OHKOHCHI, Takafumi TAMURA, Naoki SANO
  • Patent number: 9532950
    Abstract: The present invention provides a liposome having excellent lung migration ability that had not existed hitherto, by including GALA or Chol-GALA in the liposome. Furthermore, by using the liposome, a pulmonary delivery carrier having a stronger knockdown effect of siRNA when compared to existing carriers is provided.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: January 3, 2017
    Assignees: National University Corporation Hokkaido University, Taiho Pharmaceutical Co., Ltd.
    Inventors: Kenji Kusumoto, Hideyoshi Harashima, Hidetaka Akita, Hiroto Hatakeyama, Taichi Ishitsuka
  • Publication number: 20150245997
    Abstract: [Problem] To provide: a lipid membrane structure which has such a particle diameter that the lipid membrane structure can be sterilized by filtration, contains a lipid that is bound to a peptide composed of multiple arginine residues as a constituent lipid, and includes a bacterial cell component having dispersibility in a non-polar solvent; and a method for producing a lipid membrane structure which has such a particle diameter that the lipid membrane structure can be sterilized by filtration and includes a substance of interest having dispersibility in a non-polar solvent. [Solution] A lipid membrane structure which has such a particle diameter that the lipid membrane structure can be sterilized by filtration, contains a lipid that is bound to a peptide composed of multiple arginine residues as a constituent lipid, and includes a bacterial cell component having dispersibility in a non-polar solvent.
    Type: Application
    Filed: August 27, 2013
    Publication date: September 3, 2015
    Inventors: Hideyoshi Harashima, Takashi Nakamura, Masafumi Fukiage, Megumi Higuchi, Hideyuki Akaza, Jun Miyazaki, Akihiro Nakaya
  • Publication number: 20150202154
    Abstract: A lipid membrane structure for delivering a substance into a nucleus of a cell, wherein lipid membrane is modified with (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and/or (b) a polypeptide consisting of an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 1, but including deletion and/or substitution and/or insertion of one or several amino acid residues, and having an activity of promoting migration of the lipid membrane structure into a nucleus of a cell, which can efficiently deliver a nucleic acid into a nucleus of an immunocyte such as dendritic cell.
    Type: Application
    Filed: February 9, 2015
    Publication date: July 23, 2015
    Applicant: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Hideyoshi HARASHIMA, Hidetaka AKITA, Mohammad Shaheen SHARIF, Takashi NAKAMURA, Soichiro ISHII, Shiroh FUTAKI
  • Publication number: 20150140066
    Abstract: A liposome comprising a lipid covalently bonded with a polyarginine peptide consisting of 4 to 20 continuous arginine residues and a lipid covalently bonded with a GALA peptide consisting of the amino acid sequence of SEQ ID NO: 1 and/or an R-GALA peptide consisting of the amino acid sequence of SEQ ID NO: 2 as component lipids of lipid membrane, and having a lipid membrane in which a protein to be intracellularly delivered is non-covalently bound to outer surface of the membrane, which is for quickly and conveniently deriver a functional protein, especially such a protein having a high molecular weight, into a cell.
    Type: Application
    Filed: September 19, 2012
    Publication date: May 21, 2015
    Inventors: Hideyoshi Harashima, Yuma Yamada, Sandra Milena Vergara Perez, Yukari Yasuzaki
  • Patent number: 8981044
    Abstract: A lipid membrane structure for delivering a substance into a nucleus of a cell, wherein lipid membrane is modified with (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and/or (b) a polypeptide consisting of an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 1, but including deletion and/or substitution and/or insertion of one or several amino acid residues, and having an activity of promoting migration of the lipid membrane structure into a nucleus of a cell, which can efficiently deliver a nucleic acid into a nucleus of an immunocyte such as dendritic cell.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: March 17, 2015
    Assignee: National University Corporation Hokkaido University
    Inventors: Hideyoshi Harashima, Hidetaka Akita, Mohammad Shaheen Sharif, Takashi Nakamura, Soichiro Ishii, Shiroh Futaki